ES2074042T3 - Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores. - Google Patents

Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.

Info

Publication number
ES2074042T3
ES2074042T3 ES87113929T ES87113929T ES2074042T3 ES 2074042 T3 ES2074042 T3 ES 2074042T3 ES 87113929 T ES87113929 T ES 87113929T ES 87113929 T ES87113929 T ES 87113929T ES 2074042 T3 ES2074042 T3 ES 2074042T3
Authority
ES
Spain
Prior art keywords
cells
exotoxin
domain
active
pseudomonas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87113929T
Other languages
English (en)
Inventor
Ira H Pastan
David J Fitzgerald
Sankar Adhya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adidas AG
Original Assignee
Adidas Sportschuhfabriken Adi Dassier Stiftung and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adidas Sportschuhfabriken Adi Dassier Stiftung and Co KG filed Critical Adidas Sportschuhfabriken Adi Dassier Stiftung and Co KG
Application granted granted Critical
Publication of ES2074042T3 publication Critical patent/ES2074042T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

SE PRODUCEN GRANDES CATIDADES DE DIVERSAS FORMAS MODIFICADAS DE EXOTOXINA DE PSEUDONOMAS. AL MENOS UNA DE LAS FORMAS MODIFICADAS (PJH8) DE LA EXOTOXINA MUESTRA BAJA TOXICIDAD FRENTE A CELULAS HUMANAS O DE RATON POR SI MISMA, PERO RETIENE SU ACTIVIDAD ENZIMATICA Y PRODUCE UNA INMUNOTOXINA ESPECIFICA DE LAS CELULAS MUY ACTIVA, CON MUY BAJA CITOTOXICIDAD NO ESPECIFICA. ESTOS PRODUCTOS PUEDEN SER MUY UTILES COMO VACUNAS PARA PRODUCIR ANTICUERPOS PARA EL TRATAMIENTO DE SEPSIS POR PSEUDONOMAS. ADEMAS LA PROTEINA CODIFICA POR EL DOMINIO I SOLO, PUEDE SER ADMINISTRADA DIRECTAMENTE A PACIENTES PARA EL TRATAMIENTO DE SEPSIS POR PSEUDONOMAS YA QUE DICHO DOMINIO PUEDE BLOQUEAR LA UNION DE LA TOXINA A LAS CELULAS. LOS CLONES QUE CONTIENEN EL DOMINIO II, EN PARTICULAR EL PJH12 SE PUEDE UNIR A OTRAS TOXINAS QUE TENGAN BAJA ACTIVIDAD (COMO PROTEINAS CON LA CADENA DE LA RICINA A) PARA AUMENTAR SU ACTIVIDAD CITOCIDA, SIN QUE AUMENTE SU UNION NO ESPECIFICA A LAS CELULAS.
ES87113929T 1986-09-24 1987-09-23 Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores. Expired - Lifetime ES2074042T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/911,227 US4892827A (en) 1986-09-24 1986-09-24 Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects

Publications (1)

Publication Number Publication Date
ES2074042T3 true ES2074042T3 (es) 1995-09-01

Family

ID=25429936

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93113917T Expired - Lifetime ES2253734T3 (es) 1986-09-24 1987-09-23 Exotoxina recombinante de pseudomonas: construccion de una inmunotoxina activa con efectos secundarios bajos.
ES87113929T Expired - Lifetime ES2074042T3 (es) 1986-09-24 1987-09-23 Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES93113917T Expired - Lifetime ES2253734T3 (es) 1986-09-24 1987-09-23 Exotoxina recombinante de pseudomonas: construccion de una inmunotoxina activa con efectos secundarios bajos.

Country Status (19)

Country Link
US (2) US4892827A (es)
EP (2) EP0261671B1 (es)
JP (3) JP2848489B2 (es)
KR (1) KR970001563B1 (es)
AT (2) ATE311442T1 (es)
AU (1) AU618722B2 (es)
CA (1) CA1336691C (es)
DE (2) DE3752387T2 (es)
DK (2) DK173301B1 (es)
ES (2) ES2253734T3 (es)
FI (1) FI105271B (es)
IE (1) IE66223B1 (es)
IL (2) IL83971A (es)
NO (1) NO180270C (es)
NZ (1) NZ221923A (es)
PT (1) PT85777B (es)
SG (1) SG96159A1 (es)
WO (1) WO1988002401A1 (es)
ZA (1) ZA877153B (es)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
IL90190A0 (en) * 1988-05-09 1989-12-15 Us Health Vector for secretion of proteins directly into periplasm or culture medium and method for synthesizing pure proteins utilizing the same
US5206353A (en) * 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
ZA898139B (en) * 1988-11-17 1990-08-29 Hoffmann La Roche Recombinant interleukin-2 hybrid proteins
ES2085329T3 (es) * 1989-02-17 1996-06-01 Merck & Co Inc Agente anticanceroso proteico.
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
IL93723A (en) * 1989-03-22 1997-02-18 Merck & Co Inc Cystein modified truncated pseudomonas exotoxin A
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
DK0469065T3 (da) * 1989-04-21 1996-07-15 Protein Design Labs Inc Rekombinant antistof-toxin fusionsprotein
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
WO1991009965A1 (en) * 1989-12-21 1991-07-11 The United States Of America, Represented By The Secretary, United States Department Of Commerce An improved toxin for construction of immunotoxins
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
EP0509056A4 (en) * 1990-01-02 1993-02-17 Us Health Target-specific, cytotoxic, recombinant pseudomonas exotoxin
US5110912A (en) * 1990-03-02 1992-05-05 Seragen, Inc. Purification of il-2-containing hybrid compounds
JP2665827B2 (ja) * 1990-05-11 1997-10-22 アメリカ合衆国 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992013949A1 (fr) * 1991-02-08 1992-08-20 Roussel-Uclaf Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes humains ainsi que leurs applications
FR2672616B1 (fr) * 1991-02-08 1994-09-23 Roussel Uclaf Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs de lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques.
CA2079881C (fr) * 1991-02-12 2007-11-06 Thierry Hercend Sequences nucleotidiques codant pour des regions variables de chaines .beta. des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
CA2081952A1 (en) * 1991-11-08 1993-05-09 John J. Donnelly Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use
EP0646175B1 (en) * 1992-06-18 2005-12-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant pseudomonas exotoxin with increased activity
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5980895A (en) * 1995-10-13 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
ES2190799T5 (es) 1996-03-01 2008-08-16 Novartis Ag Inmunogenos peptidicos para vacunacion y tratamiento contra la alergia.
EP0941334B1 (en) 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US20030198772A1 (en) * 1997-06-26 2003-10-23 Weder Donald E. Polymeric materials having a texture or appearance simulating the texture or appearance of paper
US20020004113A1 (en) * 1997-06-26 2002-01-10 Weder Donald E. Decorative cover for flower pot or floral grouping formed of polymeric materials having a texture or appearance simulating the texture or appearance of paper
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
ATE307208T1 (de) * 1997-07-11 2005-11-15 Us Gov Health & Human Serv Pseudomonas exotoxin-a-ähnliche chimerische immunogene
US6077676A (en) * 1997-12-18 2000-06-20 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
AU2004201055B2 (en) * 1998-04-24 2007-08-23 The Regents Of The University Of California Internalizing ErbB2 antibodies
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7078486B2 (en) * 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
US20050287638A1 (en) * 2000-04-25 2005-12-29 Weigel Paul H Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
AU2001255688A1 (en) * 2000-04-25 2001-11-07 The Board Of Regents Of The University Of Oklahoma Identification and uses of a hyaluronan receptor
DK1379550T3 (da) * 2000-12-21 2009-07-06 Us Gov Health & Human Serv Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser
EP1404353A4 (en) * 2001-04-25 2006-06-14 Paul H Weigel METHOD OF USE OF A HYALURONAN RECEPTOR
ATE468348T1 (de) 2001-09-26 2010-06-15 Government Of The Us Secretary Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
IL161863A0 (en) * 2001-11-09 2005-11-20 Neopharm Inc Selective treatment of il-13 expressing tumors
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
DK2382990T3 (en) 2003-04-30 2014-12-15 Univ Zuerich Methods of treating cancer by using an immunotoxin
WO2005052006A2 (en) * 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
US7999077B2 (en) * 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
CA2583202A1 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
WO2006041906A2 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against pseudomonas infection
EP1828232A2 (en) 2004-12-22 2007-09-05 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
PL3006457T3 (pl) 2005-07-29 2018-05-30 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
EP1966246A4 (en) * 2005-12-05 2010-01-06 Trinity Biosystems Inc METHOD AND COMPOSITIONS FOR NEEDLE-FREE ADMINISTRATION OF ANTIBODIES
US20070148131A1 (en) * 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US20090305978A1 (en) * 2006-03-16 2009-12-10 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
EP1878744A1 (en) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
JP2010534061A (ja) 2007-07-20 2010-11-04 ザ ジェネラル ホスピタル コーポレイション 組換えコレラ菌外毒素
DK2197903T3 (en) 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CA2773665C (en) 2009-09-11 2018-02-20 Ira H. Pastan Improved pseudomonas exotoxin a with reduced immunogenicity
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
CA2802857C (en) 2010-06-16 2018-09-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
US9580461B2 (en) 2010-07-30 2017-02-28 Medimmune, Llc Method for purifying active polypeptides or immunoconjugates
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP3208282A1 (en) * 2010-11-30 2017-08-23 F. Hoffmann-La Roche AG Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier
ES2666550T3 (es) 2011-04-19 2018-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
MX2013014388A (es) * 2011-06-09 2014-08-21 Health Exotoxina a de pseudomonas con epitopos de linfocitos t y/o linfocitos b menos inmunogenicos.
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP2755993B1 (en) 2011-09-16 2017-11-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2013181543A1 (en) 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014031476A1 (en) 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2014093240A1 (en) 2012-12-10 2014-06-19 The General Hospital Corporation Bivalent il-2 fusion toxins
CN105007937B (zh) 2012-12-20 2019-11-19 米迪缪尼有限公司 生产免疫偶联物的方法
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
AU2014329437B2 (en) 2013-10-06 2018-10-18 F. Hoffmann-La Roche Ag Modified Pseudomonas exotoxin A
EP3620470B1 (en) 2013-10-11 2023-07-26 The United States of America, as represented by The Secretary, Department of Health and Human Services Tem8 antibodies and their use
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CA2930587A1 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
CA2937524A1 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
RU2723178C2 (ru) 2014-05-07 2020-06-09 ЭППЛАЙД МОЛЕКЬЮЛАР ТРАНСПОРТ ЭлЭлСи Слитые молекулы, происходящие от Cholix-токсина, для пероральной доставки биологически активных нагрузок
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
ES2875057T3 (es) 2014-09-17 2021-11-08 Us Health Anticuerpos anti-CD276 (B7H3)
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CA2981509A1 (en) 2015-03-30 2016-10-06 The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La Compositions comprising talens and methods of treating hiv
AU2016282986A1 (en) 2015-06-26 2018-02-01 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CN108367062B (zh) 2015-10-13 2022-05-06 赛诺菲巴斯德有限公司 抗金黄色葡萄球菌的免疫原性组合物
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017083511A1 (en) 2015-11-13 2017-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-bcma polypeptides and proteins
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
WO2018026533A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
WO2018213612A1 (en) 2017-05-18 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
AU2018268970A1 (en) 2017-05-19 2019-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
US11795235B2 (en) 2017-09-18 2023-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins with albumin binding domain
WO2019071150A1 (en) 2017-10-06 2019-04-11 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
HUE059330T2 (hu) 2018-03-08 2022-11-28 Applied Molecular Transport Inc Toxinból származó bejuttatási konstrukciók orális beadásra
EP3820903A1 (en) 2018-07-12 2021-05-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
KR102353086B1 (ko) * 2018-09-07 2022-01-20 아주대학교산학협력단 신규 면역독소 제조방법
JP2022506990A (ja) 2018-11-07 2022-01-17 アプライド モレキュラー トランスポート インコーポレイテッド トランスサイトーシスのための送達構築物および関連する方法
JP2022512976A (ja) 2018-11-07 2022-02-07 アプライド モレキュラー トランスポート インコーポレイテッド 異種ペイロードの経口送達のためのコリックス由来担体
CN113490510A (zh) 2019-01-08 2021-10-08 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
EP3883971A1 (en) 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2020172344A1 (en) 2019-02-19 2020-08-27 The Regents Of The University Of Colorado, A Body Corporate Bispecific immunotoxins targeting human cd25+ccr4+ tumors and regulatory t-cells
US20220380474A1 (en) 2019-07-02 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Monoclonal antibodies that bind egfrviii and their use
EP3844169A4 (en) 2019-08-16 2021-12-15 Applied Molecular Transport Inc. COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKINS
US20220380471A1 (en) 2019-10-22 2022-12-01 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7-h3 (cd276) for treating multiple solid tumors
WO2021097289A1 (en) 2019-11-15 2021-05-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pegylated recombinant immunotoxins
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CA3202875A1 (en) 2020-12-22 2022-06-30 Huan Wang Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
AU2022291120A1 (en) 2021-06-09 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
WO2023114980A1 (en) 2021-12-17 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470924A (en) * 1981-12-30 1984-09-11 Iglewski Barbara M Nontoxic, immunologically crossreactive toxin A protein from Pseudomonas aeruginosa
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
ES8708014A1 (es) * 1984-06-07 1987-09-01 Murphy John R Un procedimiento para preparar un gen fusionado que codifica una proteina hibrida susceptible de marcado y empleo en diagnosis.
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies

Also Published As

Publication number Publication date
FI891321A (fi) 1989-03-21
NO882269L (no) 1988-05-24
DE3789587T2 (de) 1994-07-28
DE3789587D1 (de) 1994-05-19
DE3752387T2 (de) 2006-06-08
EP0583794A1 (en) 1994-02-23
PT85777B (pt) 1990-07-31
AU618722B2 (en) 1992-01-09
KR890700162A (ko) 1989-03-10
IL105160A (en) 1997-07-13
IE950321L (en) 1988-03-24
DK276488A (da) 1988-05-20
NO882269D0 (no) 1988-05-24
ES2253734T3 (es) 2006-06-01
FI891321A0 (fi) 1989-03-21
DK276488D0 (da) 1988-05-20
DK199901377A (da) 1999-09-28
EP0261671A3 (en) 1988-08-10
SG96159A1 (en) 2003-05-23
DE3752387D1 (de) 2006-01-05
NO180270B (no) 1996-12-09
EP0583794B1 (en) 2005-11-30
JP2960697B2 (ja) 1999-10-12
NO180270C (no) 1997-03-19
US5696237A (en) 1997-12-09
EP0261671B1 (en) 1994-04-13
ZA877153B (en) 1989-08-30
WO1988002401A1 (en) 1988-04-07
JPH10136988A (ja) 1998-05-26
ATE104153T1 (de) 1994-04-15
NZ221923A (en) 1991-12-23
DK173560B1 (da) 2001-03-12
IE66223B1 (en) 1995-12-13
FI105271B (fi) 2000-07-14
AU8021187A (en) 1988-04-21
CA1336691C (en) 1995-08-15
IE872553L (en) 1988-03-24
IL83971A (en) 1994-06-24
PT85777A (en) 1987-10-01
EP0261671A2 (en) 1988-03-30
IL83971A0 (en) 1988-02-29
US4892827A (en) 1990-01-09
JPH02502063A (ja) 1990-07-12
JP3053087B2 (ja) 2000-06-19
JP2848489B2 (ja) 1999-01-20
DK173301B1 (da) 2000-06-19
KR970001563B1 (ko) 1997-02-11
ATE311442T1 (de) 2005-12-15
JPH11253181A (ja) 1999-09-21

Similar Documents

Publication Publication Date Title
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
AR007249A1 (es) Preparacion concentrada de anticuerpos
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
CY1112927T1 (el) Αντισωματα κατα της ανθρωπινης il-12
ATE251942T1 (de) Stapelbare statische mischelemente
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
DE69333951D1 (de) Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
ATE312909T1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
ES2183351T3 (es) Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
EA200200904A1 (ru) Структуры в растворе и в кристалле активного центра ммр-13 и их применение
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ES2118058T3 (es) Factor de crecimiento de las celulas t.
NO971059L (no) Modifiserte human-C3-proteiner
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
IT1270618B (it) Proteine ad attivita' antitumorale
DE58906338D1 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Kaliumkanal-Modulatoren sowie deren Verwendung in Arzneimitteln.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
ES2174103T3 (es) Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
ES2186166T3 (es) Peptido natriuretico atrial (anp) como aditivo para soluciones de dialisis peritoneal.
ES2180750T3 (es) Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 261671

Country of ref document: ES